HSP90B1 and neoplasm: Recent Phase III clinical trials using autologous, tumor-derived gp96 on patients with renal cell carcinoma or melanoma did not achieve the overall stated endpoints although a subset of patients, those with early disease stage, did benefit from the vaccine to survive longer than those in the control arm8, 9.